Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
Patents for C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
10/2007
10/24/2007EP1534671A4 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
10/24/2007CN101058616A Crosslinking polymer containing cavity transmission unit of 8-hydroxyquinoline metal complex and preparation method
10/24/2007CN101058564A Aryl alkyl carbamate derivatives production and use thereof in therapy
10/24/2007CN101058558A 4-Oxy-1(4H)-quinoline carboxylic acids compound and composition with aldose reductase inhibition activity and preparation method thereof
10/23/2007US7285662 Therapeutic heterocyclic compounds
10/23/2007US7285563 e.g. N-Benzyl-N'-isoquinolin-5-ylurea; treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1)
10/18/2007WO2007118041A1 Compounds which modulate the cb2 receptor
10/18/2007WO2007117161A1 Substituted ring fused azines and their use in cancer therapy
10/18/2007WO2007116922A1 A process for preparing tetrahydroquinoline derivatives
10/18/2007WO2007116314A1 N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites
10/18/2007WO2007116240A1 An improved process for the manufacture of montelukast sodium
10/18/2007WO2007115935A1 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
10/18/2007US20070244197 Bactericide against gramnegative bacteria; respiratory system disorders
10/18/2007US20070244156 Sulfonylamino-acetic acid derivatives
10/18/2007US20070244154 Substituted Tricyclic Benzimidazoles
10/18/2007US20070244124 For therapy of multi-drug resistant disease; combination therapy; anticarcinogenic agent; leukemia; hydrochloride salt; obtained with copper radiation source
10/18/2007US20070244116 c-MET MODULATORS AND METHOD OF USE
10/18/2007US20070244053 Use of a CD40:CD154 binding interruptor to prevent counter-adaptive immune responses, particularly graft rejection
10/18/2007CA2649189A1 An improved process for the manufacture of montelukast sodium
10/18/2007CA2648978A1 N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites
10/18/2007CA2648323A1 Substituted ring fused azines and their use in cancer therapy
10/18/2007CA2648074A1 11.beta.-hydroxysteroid dehydrogenase type 1 active compounds
10/18/2007CA2643863A1 Compounds which modulate the cb2 receptor
10/18/2007CA2643011A1 Quinolones useful as inducible nitric oxide synthase inhibitors
10/17/2007EP1845088A1 An improved process for the preparation of aripipirazole
10/17/2007EP1844766A2 Inhibitors against the production and release of inflammatory cytokines
10/17/2007EP1844045A1 Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors
10/17/2007EP1844016A1 Polymorph and solvates of aripiprazole
10/17/2007EP1844015A2 Novel heterocyclic oxime derivatives, method for preparing same and pharmaceutical compositions containing same
10/17/2007EP1843766A1 Antidiabetic bicyclic compounds
10/17/2007CN101056859A Quinoline derivatives as isotope labeling for adenosine a3 receptor ligand
10/17/2007CN101056845A Substituted aniline derivatives
10/17/2007CN101056635A Niacin receptor agonists, compositions containing such compounds and methods of treatment
10/17/2007CN101054330A Synthesis method for biphenyl compound
10/16/2007US7282585 Salt and crystalline forms of (2R)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline
10/16/2007US7282583 Process for making 5,11-Dihydro-11-ethyl-5-methyl-8{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-di pyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one
10/11/2007WO2007114672A1 Agent for the prevention and treatment of metabolic bone disease by enhancing osteoprotegerin secretion
10/11/2007WO2007114213A1 Substituted bicyclic cyclic derivative and use thereof
10/11/2007WO2007113846A1 A process for the preparation of aripiprazole
10/11/2007WO2007075901A3 Quinolin- 4 - one derivatives as modulators of abc transporters
10/11/2007US20070238736 4-(1-Piperazinyl)-2(1H)-quinolone and 4-(1-piperazinyl)quinoline derivatives, e.g., 4-[4-(Benzo [1,3]dioxole-5-carbonyl)-piperazin-1-yl]-1-(4-fluoro-benzyl)-2-oxo-1,2-dihydro-quinoline-3-carbonitrile; antitumor and angiogenesis inhibitor, antiinflammatory, antidiabetic agent, autoimmune disorder
10/11/2007US20070238714 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
10/11/2007US20070237824 Sustained-Release Preparations Of Quinolone Antibiotics
10/11/2007DE60022050C5 Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems Metabotropic glutamate receptor antagonists for treating diseases of the central nervous system
10/11/2007CA2647811A1 Substituted bicyclic derivative and use thereof
10/10/2007EP1841743A1 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity
10/10/2007EP1841504A2 Substituted biaryl compounds as factor xia inhibitors
10/10/2007EP1756029B1 Novel compounds, the preparation and the use thereof for a regiospesific synthesis of perfluor(alkyl) group heterocycles
10/10/2007EP1232150B1 Urea derivatives as anti-inflammatory agents
10/10/2007CN101052630A Substituted heterocyclic compounds and uses thereof
10/10/2007CN101052621A 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
10/10/2007CN101052401A Use of unsaturated quionoline or naphtalene derivatives as medicaments
10/10/2007CN101052399A Chemical compounds
10/10/2007CN101050189A Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids
10/10/2007CN100341855C 7-substituted-8-methoxy fluoroquinolone carboxylic derivatives, preparing process, preparation and use thereof
10/09/2007US7279578 Use as orexin receptor antagonists, depression; anxiety; addictions; obsessive compulsive disorder; affective neurosis; depressive neurosis; anxiety neurosis; dysthymic disorder; behaviour disorder; mood disorder; sexual dysfunction; psychosexual dysfunction; schizophrenia; manic depression; delerium
10/09/2007US7279573 Benzodiazepine derivatives that may be fused to a pyrroline or piperidine ring; e.g., N-[1 (R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H-(11aS)-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)propionamide; increasing levels of endogenous growth hormones in humans and animals
10/09/2007US7279481 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone; therapy of depression or anxiety
10/09/2007US7279478 Cathepsin cysteine protease inhibitors
10/09/2007US7279470 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
10/04/2007WO2007112347A1 Dipeptidyl peptidase inhibitors
10/04/2007WO2007111027A1 Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
10/04/2007WO2007092846A3 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
10/04/2007WO2007027999A3 Chemical compounds
10/04/2007US20070232806 Reacting 2S,4S)-1-(1,1-Dimethylethyl)-4-methyl-5-oxo-1,2-pyrrolidinedicarboxylic acid-2-methyl ester sodium borohydride in alkanol to form 1S,3S)-(4-Hydroxyl-1-hydroxymethyl-3-methyl-butyl)-carbamic acid tert-butyl ester; for making acyclic diol intermediates from cyclic intermediates
10/04/2007US20070232654 Novel Compounds and Compositions as Cathepsin Inhibitors
10/04/2007US20070232651 Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof
10/04/2007US20070232643 Quinoline derivative, e.g. 2[4-(7-chloroquinolin-2-yloxy)phenoxy]propionic acid sodium salt; anticarcinogenic, antitumor agent; colon, breast, melanoma, pancreatic cancer or adenocarcinoma; melanoma, or leukemia; based on herbicides
10/04/2007US20070232642 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of beta-secretase (bace)
10/04/2007US20070232636 schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, COPD and micturition disorders such as urinary incontinence
10/04/2007US20070232615 Chemical Compounds
10/04/2007US20070232613 4-(1-Piperazinyl)-2(1H)-quinolone and 4-(1-piperazinyl)quinoline derivatives, e.g., 3-nitro- or 3-alkoxycarbonyl-1-methyl-4-[4-thiophene-2-carbonyl)-piperazine-1-yl]-1H-quinolin-2-one; antitumor and angiogenesis inhibitor, antiinflammatory, antidiabetic agent, autoimmune disorder
10/04/2007US20070232572 Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
10/04/2007CA2645281A1 Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
10/04/2007CA2644369A1 Amide derivatives and their application for the treatment of g protein related diseases
10/03/2007EP1838690A2 Compounds with kv4 ion channel activity
10/03/2007EP1838296A2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
10/03/2007EP1622874B1 3,4-dihydro-1h-quinolin-2-one derivatives as norepinephrine reuptake inhibitors
10/03/2007EP1448530B1 Heteroaryl carboxylic acid amides
10/03/2007CN101048384A Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
10/03/2007CN101048367A New tyrosine derivative as ppar gamma regulator
10/03/2007CN101045725A Malate and multicrystal object of some quinolone compound
10/03/2007CN101045724A Coupling method for preparing quinolone intermediate
10/02/2007US7276726 Electroluminescent iridium compounds with fluorinated phenylpyridines, phenylpyrimidines, and phenylquinolines and devices made with such compounds
10/02/2007US7276612 For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides
10/02/2007US7276608 3-(amino)sulfonylamino-substituted, e.g., N-(1,6-Dibenzyl-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-benzenesulfonamide and N-(1-Benzyl-2-oxo-6-(thiophen-3-yl)-1,2,3,4-tetrahydroquinolin-3-yl)benzenesulfonamide; eating, metabolic, obesity, cognitive, neurological, pain, inflammatory and psychiatric disorders
10/02/2007US7276522 dextrorotatory and levo-rotatory enantiomers; specific to alpha2B adrenergic receptors
10/02/2007CA2096407C Retroviral protease inhibitors
09/2007
09/27/2007WO2007109175A1 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
09/27/2007WO2007107828A2 Amine derivatives
09/27/2007WO2007107352A1 Agents that disrupt cellular replication and their use in inhibiting pathological conditions
09/27/2007WO2007107311A2 Organic sulphinic acid derivatives
09/27/2007WO2007107297A1 Montelukast amantadine salt
09/27/2007WO2007107246A2 SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM
09/27/2007WO2007022241A3 Novel high affinity quinoline-based kinase ligands
09/27/2007US20070225506 Bactericides; 2-[(1R)-1-methyl-2-trityl-2,3-dihydro-1H-5-isoindolyl]-1,3,6,2-dioxazaborocane.
09/27/2007US20070225365 Cetp Inhibitors
09/27/2007US20070225329 Aryl aniline beta2 adrenergic receptor agonists
09/27/2007US20070225327 3-Methyl-2-[4'-(pyridin-3-ylmethoxymethyl)-biphenyl-4-sulfonylamino]-butyric acid; metalloproteinase inhibitors; arthritis, macular degeneration, graft versus host disease, cancer, osteoarthritis
09/27/2007US20070225326 Useful for isolation and purification of the montelukast acid before its conversion to montelukast sodium
1 ... 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 ... 277